---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-032458"
form_type: "8-K"
ticker: null
cik: "0000827871"
company_name: "EAGLE PHARMACEUTICALS, INC."
filed_at: "2024-03-08T23:59:59+00:00"
generated_at: "2026-06-05T00:57:38.182597+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Eagle Pharma CFO Brian Cahill resigns effective immediately; Steven Ratoff named Interim CFO

## Summary
- CFO Brian Cahill resigned March 8, 2024; separation includes cash severance of $423,340 base plus $254,004 target bonus paid over 12 months.
- Director Steven Ratoff appointed Interim CFO; to receive $154,000/month for first 3 months, $77,000/month thereafter, term <12 months.
- Cahill’s time-based equity awards continue outstanding for 12 months, then vest for those scheduled during that period; performance awards forfeited.
- Consulting services of former CEO Scott Tarriff terminated effective Feb 29, 2024.
- Board committee changes: Ratoff steps down from Audit and Compensation; Jennifer Simpson named Lead Independent Director.

## SEC filing metadata
- accession: 0001104659-24-032458
- form_type: 8-K
- cik: 0000827871
- company_name: EAGLE PHARMACEUTICALS, INC.
- filed_at: 2024-03-08T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/827871/000110465924032458/0001104659-24-032458-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/827871/000110465924032458/tm248308d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-032458
- JSON: https://secwatch.observer/filing/0001104659-24-032458.json
- Plain text: https://secwatch.observer/filing/0001104659-24-032458.txt

## Key facts
- Executive change
  Brian Cahill resigned as Chief Financial Officer at EAGLE PHARMACEUTICALS, INC..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On March 8, 2024, Brian Cahill resigned from his position as Chief Financial Officer of Eagle Pharmaceuticals, Inc. (the “Company”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/827871/000110465924032458/0001104659-24-032458-index.htm
- Executive change
  Steven Ratoff was appointed as Interim Chief Financial Officer at EAGLE PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Interim Chief Financial Officer
  source text: Steven Ratoff, a member of the Board and Chair of the Audit Committee of the Board (the “Audit Committee”), was appointed Interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of the Company, effective immediately
  evidence_url: https://www.sec.gov/Archives/edgar/data/827871/000110465924032458/0001104659-24-032458-index.htm
- Executive change
  Jennifer Simpson was appointed as Lead Independent Director at EAGLE PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Lead Independent Director
  source text: the Board appointed Dr. Simpson to serve as the Lead Independent Director of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/827871/000110465924032458/0001104659-24-032458-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.